Ke-hong Chen

Ke-hong Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in The FASEB Journal
Verified
Journal Article
Closed access
JCJia Chen
Jia Chen
HLHongxiang Lu
Hongxiang Lu
XWXiaoyue Wang
Xiaoyue Wang
JYJie Yang
Jie Yang
JLJia Luo
Jia Luo
KCKe-hong Chen
Ke-hong Chen

30 July 2025 in Cell Reports
Verified
Journal Article
Open access
FYFang Yu
Fang Yu
YMYan Meng
Yan Meng
XWXiaoyue Wang
Xiaoyue Wang
JCJia Chen
Jia Chen
JHJunling He
Junling He
KCKe-hong Chen
Ke-hong Chen
Interstitial renal inflammation contributes to the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). Recently, lactylation modification has emerged as a mechanism for mediating chronic organ damage. We investigate lactylated protein profiles and the role of protein lactylation during the progression of AKI. In vitro and in vivo experiments demonstrate that protein lactylation activates Nod-like receptor protein 3 (NLRP3) inflammasomes, promoting the AKI-CKD transition. Comprehensive lactylome profiling shows that lactylated proteins are involved in metabolic pathways, particularly the tricarboxylic acid cycle. Notably, the rate-limiting enzyme citrate synthase (CS) exhibits significantly elevated lactylation levels post-AKI induction, and K370 was the most significant lysine residue. In vitro, the modified/lactylated K370T group significantly decreases CS activity and mitochondrial function and activates the NLRP3 inflammasomes. Thus, CS lactylation promotes the AKI-CKD transition via NLRP3 inflammasome activation, suggesting that inhibiting CS lactylation may offer therapeutic potential for preventing this transition.

2 January 2024 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
JWJingfang Wan
Jingfang Wan
LFLei Feng
Lei Feng
SHShihui Hou
Shihui Hou
KYKaizhen Yv
Kaizhen Yv
KCKe-hong Chen
Ke-hong Chen
Background: An appropriate prediction model for adverse prognosis before peritoneal dialysis (PD) is lacking. Thus, we retrospectively analysed patients who underwent PD to construct a predictive model for adverse prognoses using machine learning (ML). Methods: A retrospective analysis was conducted on 873 patients who underwent PD from August 2007 to December 2020. A total of 824 patients who met the inclusion criteria were included in the analysis. Five commonly used ML algorithms were used for the initial model training. By using the area under the curve (AUC) and accuracy (ACC), we ranked the indicators with the highest impact and displayed them using the values of Shapley additive explanation (SHAP) version 0.41.0. The top 20 indicators were selected to build a compact model that is conducive to clinical application. All model-building steps were implemented in Python 3.8.3. Results: At the end of follow-up, 353 patients withdrew from PD (converted to haemodialysis or died), and 471 patients continued receiving PD. In the complete model, the categorical boosting classifier (CatBoost) model exhibited the strongest performance (AUC = 0.80, 95% confidence interval [CI] = 0.76–0.83; ACC: 0.78, 95% CI = 0.72–0.83) and was selected for subsequent analysis. We reconstructed a compression model by extracting 20 key features ranked by the SHAP values, and the CatBoost model still showed the strongest performance (AUC = 0.79, ACC = 0.74). Conclusions: The CatBoost model, which was built using the intelligent analysis technology of ML, demonstrated the best predictive performance. Therefore, our developed prediction model has potential value in patient screening before PD and hierarchical management after PD.

17 July 2023 in Heliyon
Verified
Journal Article
Open access
JCJia Chen
Jia Chen
QZQuan-You Zheng
Quan-You Zheng
LWLi-Ming Wang
Li-Ming Wang
JLJia Luo
Jia Luo
KCKe-hong Chen
Ke-hong Chen
YHYani He
Yani He
Acute kidney injury (AKI) is characterized by a rapid decrease in renal function with high mortality and risk of progression to chronic kidney disease (CKD). Ischemia and reperfusion injury (IRI) is one of the major causes of AKI. However, the cellular and molecular responses of the kidney to IRI are complex and not fully understood. Herein, we conducted unbiased proteomics and bioinformatics analyses in an IRI mouse model on days 3, 7, and 21, and validated the results using IRI, unilateral ureteral obstruction (UUO), and biopsies from patients with AKI or CKD. The results indicated an obvious temporal expression profile of differentially expressed proteins and highlighted impaired lipid metabolism during the progression of AKI to CKD. Acyl-coenzyme A oxidase 1 (Acox1), the first rate-limiting enzyme of peroxisomal fatty acid beta-oxidation, was then selected, and its disturbed expression in the two murine models validated the proteomic findings. Accordingly, Acox1 expression was significantly downregulated in renal biopsies from patients with AKI or CKD, and its expression was negatively correlated with kidney injury score. Furthermore, in contrast to the decreased Acox1 expression, lipid droplet accumulation was remarkably increased in these renal tissues, suggesting dysregulation of fatty acid oxidation. In conclusion, our results suggest that defective peroxisomal fatty acid oxidation might be a common pathological feature in the transition from AKI to CKD, and that Acox1 is a promising intervention target for kidney injury and repair.

1 April 2023 in Stem Cells and Development
Verified
Journal Article
Closed access
FYFang Yu
Fang Yu
JYJie Yang
Jie Yang
JCJia Chen
Jia Chen
XWXiaoyue Wang
Xiaoyue Wang
QCQingli Cai
Qingli Cai
KCKe-hong Chen
Ke-hong Chen
Peritoneal fibrosis is a critical sequela that limits the application of peritoneal dialysis (PD). This study explored the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) in preventing PD-associated peritoneal injury. C57BL/6 mice were randomized into three groups: a control (saline), peritoneal injury (2.5% glucose peritoneal dialysate + lipopolysaccharide (LPS)), and peritoneal injury + exosome group. After six weeks, mice were dissected, and the parietal peritoneum was collected. The level of peritoneal structural and functional damage was assessed. Additionally, transcriptome analysis of the peritoneum and miRNA sequencing on BMSC-Exos were performed. The parietal peritoneum had significantly thickened, and peritoneal function was impaired in the peritoneal injury group. Peritoneal structural and functional damage was significantly reduced after exosome treatment, while peritoneal inflammation, fibrosis, angiogenesis, and mesothelial damage significantly increased. Transcriptomic analysis showed that the BMSC-Exos affected the cell cycle process, cell differentiation, and inflammatory response regulation. Significant pathways in the exosome group were enriched by inflammation, immune response, and cell differentiation, which constitute a molecular network that regulates the peritoneal protective mechanism. Additionally, inflammatory factors (TNF-α, IL-1β), fibrosis markers (α-SMA, collagen-III, fibronectin), profibrotic cytokines (TGF-β1), and angiogenesis-related factor (VEGF) were downregulated at the mRNA and protein levels through BMSC-Exos treatment. BMSC-Exos treatment can prevent peritoneal injury by inhibiting peritoneal fibrosis, inflammation, and angiogenesis, showing a multi-target regulatory effect. Therefore, BMSC-Exos therapy might be a new therapeutic strategy for treating peritoneal injury.

30 March 2022 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
FYFang Yu
Fang Yu
JCJia Chen
Jia Chen
XWXiaoyue Wang
Xiaoyue Wang
QCQingli Cai
Qingli Cai
JLJia Luo
Jia Luo
YHYani He
Yani He